MTSI arrives at Thursday's Q1 earnings call with its best week in months already in the bag — and the Street has been raising targets faster than the stock has been moving.
The week's standout is price action. MACOM Technology Solutions closed at $303.57 on Tuesday, up 14.3% on the week and 27.4% over the past month. That rally has pushed the stock past the mean analyst price target of $283, which is now below the current price — a sign that the Street has been playing catch-up rather than leading. The most recent analyst moves, both from late April, support the bullish direction: Stifel lifted its target to $300 and B of A Securities raised to $305, both maintaining Buy. Loop Capital also started coverage with a Buy and $300 target in mid-April. Overall, analysts are grouped firmly in the constructive camp, though the convergence of current price and Street targets means the upside math is getting tighter ahead of tomorrow's print.
The earnings setup deserves attention. The last two quarters both produced positive reactions. Q1 FY2026 (reported February) saw the stock gain nearly 10% the next day and extend that to 11% over the following week. The prior quarter added 3.5% on the day and 7% over five days. The next event is confirmed for May 7 at 12:30 UTC — tomorrow morning — which puts all of this week's positioning directly in context.
Short interest tells a quiet story heading into the print. Bears have been exiting steadily: SI has fallen 12.2% over the past week and 16.1% over the past month, landing at 3.6% of free float — a level too modest to imply any meaningful squeeze dynamic. Borrowing costs are near flat at 0.53% annually, and availability remains wide. The ORTEX short score has dropped from 41 in late April to 37.5 this week, tracking the covering trend. This is not a setup where short-side pressure is a major factor in either direction.
Options positioning confirms the bullish lean. The put/call ratio dropped sharply to 0.39 on Tuesday, well below the 20-day average of 0.37 — slightly below-average hedging demand, not above it. The z-score of 0.31 is barely above neutral. For context, the 52-week PCR range runs from 0.07 to 0.73; at 0.39, options traders are neither especially defensive nor aggressively long. The overall tone is one of calm confidence rather than event-driven hedging.
Institutional ownership confirms the stock has earned a broad investor base. FMR (Fidelity) and BlackRock each hold over 10% of shares, with T. Rowe Price and Vanguard each near 9.7–9.8%. FMR added 1.55 million shares in the most recently reported period, a meaningful step-up. The insider activity in the snapshot is limited to a series of small SVP sales totalling roughly $1 million on April 30, all at prices well below current levels — routine, low-significance transactions rather than a directional signal. Valuation has re-rated sharply alongside the price: the P/E has expanded to 62x, up 13 points over the past month, and P/B moved to 13.7x. EV/EBITDA of 55x is not cheap, and the factor score for EV/EBIT ranks in the bottom decile of the universe — bears will flag valuation as the clearest risk.
Among peers, SITM gained 15.7% on the week and SMTC surged 19.7%, suggesting a broad-based analog/mixed-signal semiconductor bid rather than an MACOM-specific move. MACOM's 14.3% gain is in line with this cohort — the sector tailwind is real, which means tomorrow's report has to answer whether MACOM's own execution justifies the incremental premium over its peers.
See the live data behind this article on ORTEX.
Open MTSI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
